JW (Cayman) Therapeutics Co. Ltd (HKG:2126)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
1.960
+0.100 (5.38%)
At close: Mar 27, 2026
Market Cap795.05M -6.5%
Revenue (ttm)315.65M +79.3%
Net Income-617.93M
EPS-1.49
Shares Out405.64M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume880,000
Average Volume967,125
Open1.860
Previous Close1.860
Day's Range1.860 - 2.000
52-Week Range1.260 - 6.440
Beta1.97
RSI46.57
Earnings DateMar 26, 2026

About HKG:2126

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People’s Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) immunotherapy for use in the treatment of a range of hematological ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 292
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2126
Full Company Profile

Financial Performance

In 2025, HKG:2126's revenue was 283.65 million, an increase of 79.28% compared to the previous year's 158.22 million. Losses were -555.29 million, -5.98% less than in 2024.

Financial numbers in CNY Financial Statements